Format

Send to

Choose Destination
Nervenarzt. 2016 Apr;87(4):356-66. doi: 10.1007/s00115-016-0095-z.

[Significance of the German Act on the Reform of the Market for Medicinal Products for psychopharmacotherapy].

[Article in German]

Author information

1
Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Uniklinik RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland. ggruender@ukaachen.de.

Abstract

The German Act on the Reform of the Market for Medicinal Products (AMNOG) will lead to rapid disappearance of many new psychotropic drugs from the market in Germany over the next few years or their not being introduced in the first place. This article lists the reasons and discusses possible solutions. In the long term, the AMNOG could not only lead to an improvement of psychopharmacology but also contribute to the development of psychiatry as a whole, especially if its standards become an international reference.

KEYWORDS:

Benefit risk assessment; Clinical trial; Drug evaluation; Health technology assessment; Psychopharmacology

PMID:
26983820
DOI:
10.1007/s00115-016-0095-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center